ActoGeniX - About the company
ActoGeniX is an acquired company based in Ghent (Belgium), founded in 2006. It operates as an Engineering microbes for in situ expression and secretion of novel biotherapeutic proteins and peptides.. ActoGeniX has raised $57.2M in funding. The company has 351 active competitors, including 140 funded and 83 that have exited. Its top competitors include companies like Ginkgo Bioworks, Syngenta and Spark Therapeutics.
Company Details
ActoGeniX is focused on the development and commercialization of ActoBiotics™, a novel class of orally available biopharmaceuticals for the targeted treatment of severe diseases. Its proprietary TopAct platform developed enables the molecular engineering of food-grade microbes (lactococcus lactis) to generate biologically-contained ActoBiotics™ for in situ expression and secretion of novel biotherapeutic proteins and peptides including cytokines, enzymes, hormones, and monoclonal antibodies to the oral and gastrointestinal tract. Its clinical stage products include AG013 which delivers a therapeutic peptide for the prevention and attenuation of oral mucositis, and AG014 which secretes anti-TNF-alpha Fab to treat inflammatory bowel disease with localized delivery minimizing systemic exposure. Acobiotics has the potential to facilitate targeted therapies against oral, gastrointestinal, metabolic, allergic and autoimmune diseases. The company has been acquired by Intrexon Corp. on Feb 2015.
- Website
- actogenix.com
Key Metrics
Founded Year
2006
Location
Ghent, Belgium
Stage
Acquired
Total Funding
$57.2M in 4 rounds
Latest Funding Round
Investors
Ranked
152nd among 351 active competitors
Employee Count
5 as on Jul 31, 2026
Similar Companies
Exit Details
Acquired by Precigen (Feb 13, 2015)
ActoGeniX's acquisition details
Click here to take a look at ActoGeniX's acquisition in detail
Sign up to download ActoGeniX's company profile
ActoGeniX's funding and investors
ActoGeniX has raised a total funding of $57.2M over 4 rounds. Its first funding round was on Feb 06, 2007. Its latest funding round was a Series B round on Apr 18, 2013 for $*****. 6 investors participated in its latest round. ActoGeniX has 10 institutional investors.
Here is the list of recent funding rounds of ActoGeniX:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 18, 2013 | 8672356 | Series B | 4079232 | 6832407 | 6999097 | 8376878 |
Feb 11, 2009 | 9021037 | Series A | 5278192 | 3547504 | 3578992 | |
Jul 12, 2007 | 7714175 | Grant (prize money) | 1962183 | 2268203 | 2135120 |
View details of ActoGeniX's funding rounds and investors
ActoGeniX's founders and board of directors
Founder? Claim ProfileActoGeniX's employee count trend
ActoGeniX has 5 employees as of Jul 26. Here is ActoGeniX's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ActoGeniX's Competitors and alternates
Top competitors of ActoGeniX include Ginkgo Bioworks, Syngenta and Spark Therapeutics. Here is the list of Top 10 competitors of ActoGeniX, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Ginkgo Bioworks 2008, Boston (United States), Public | Autonomous labs for biotechnology, empowering scientists to design the living world | $796M | 81/100 | |
2nd | Syngenta 2000, Basel (Switzerland), Acquired | Developer of technologies and sustainable farming practices for farmers | - | 75/100 | |
3rd | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
4th | Twist Bioscience 2013, San Francisco (United States), Public | Developer of a semiconductor-based DNA synthesis platform | $321M | 72/100 | |
5th | Beam Therapeutics 2017, Cambridge (United States), Public | Developer of gene therapy using CRISPR base editing to treat diseases | $222M | 70/100 | |
6th | Passage Bio 2017, Philadelphia (United States), Public | Developer of gene therapies for CNS rare diseases | $226M | 69/100 | |
7th | Codexis 2002, Redwood City (United States), Public | Developer of high-performance enzymes for drug discovery | $111M | 68/100 | |
8th | AskBio 2001, Durham (United States), Acquired | Developer of AAV technologies for treating genetic and complex disorders | $235M | 68/100 | |
9th | Developer of mRNA-based therapeutics against cancer and infectious diseases | $975M | 67/100 | ||
10th | Antheia 2013, Palo Alto (United States), Series C | Genetically engineered yeast cells to produce medicinal products | $176M | 67/100 | |
152nd | Engineering microbes for in situ expression and secretion of novel biotherapeutic proteins and peptides. | $57.2M | 37/100 |
Looking for more details on ActoGeniX's competitors? Click here to see the top ones
ActoGeniX's Investments and acquisitions
ActoGeniX has made no investments or acquisitions yet.
News related to ActoGeniX
•
Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of DirectorsBusiness Wire•Feb 06, 2024•Septerna, ActoGeniX
•
ActoGeniX completes equity financing round of EUR 13.5 | FierceBiotechFierce Biotech•Feb 11, 2009•ActoGeniX, Gimv, Baekeland Funds, VIB and 3 others
•
•
ActoGeniX Series B to Move IBD Program to IND Stage | BioWorldBioWorld•ActoGeniX, Saffelberg Investments, Gimv, Baekeland Funds and 3 others
•
ActoGeniX closes EUR 10.7 million financing roundLife Sciences Partners•ActoGeniX, Saffelberg Investments, Gimv, Baekeland Funds and 3 others
•
Are you a Founder ?
FAQs about ActoGeniX
Explore our recently published companies
- Active in Time - Northampton based, 2011 founded, Public company
- Ac Nutrition - Winters based, Unfunded company
- Akitg - Ourense based, 2005 founded, Unfunded company
- Access Engineering - Unfunded company
- Albion Sports - Sydney based, 2021 founded, Unfunded company
- 3PointLight - Mumbai based, 2011 founded, Unfunded company